SDS Optic Revenue and Competitors

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 783818. SDS Optic Vision is to save 30% of people deadly sick on cancer by 2030. It will be achieved thanks to innovative real-time results microprobe cancer diagnostics tool set which will lead to much faster and much more effective targeted cancer treatment. SDS Optic, headquartered in Lublin, is a highly innovative growing biotech company, focused on development of novel diagnostic strategies in the field of oncology. Company develops and innovates diagnostics solutions, responding to needs of patients with cancer and focusing on helping the healthcare with faster and less painful diagnostics. Our Mission is „Saving, Monitoring and Improving Lives through Innovative Cancer Diagnostics Solutions”. SDS Optic has developed innovative analytical technology, capable of interacting with living tissues and cells in vivo, delivered as a two-part set: diagnostic microprobe and detecting device. It identifies cancer cells with laser fiber optics of specific frequency through innovative components inside the microprobe. All data is transformed via fiber optics into a multi-mode detection device, where data is calculated using specific algorithms, and which may immediately be printed out during testing. This is presented numerically with exact levels of tested compounds. Thanks to high detection sensitivity in cancer diagnostics this technology allows close proximity of the tumor, omitting invasion, as currently performed and which may cause malignancy. Key benefits of the SDS Optic Microprobe are: • Sensitivity – much higher than currently available (no need for tumor invasion) • Real-Time diagnostics • Micro-size needle and probe – less pain for patients • Reduced healthcare expenses and treatment cost